EC359 NEW
| Price | $117 |
| Package | 1mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: EC359 | CAS No.: 2012591-09-0 |
| Purity: 98.11% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | EC359 |
| Description | EC359 is a potent and selective inhibitor of leukemia inhibitory factor receptor (LIFR), a potent inhibitor with anticancer activity, blocks LIF/LIFR interaction, and can be used in the study of leukemia and endometrial cancer. |
| In vitro | EC359 treatment (0-100 nM) for 3 days in BT-549, SUM-159, MDA-MB-231, MDA-MB-468, and HCC1806 cells leads to a dose-dependent reduction in cell viability[1]. In MDA-MB-231 and BT-549 cells, treatment with EC359 at concentrations of 20 nM and 25 nM for 72 hours significantly increases caspase-3/7 activity and the proportion of Annexin V-positive cells. EC359 exhibits noteworthy inhibitory activity on invasion and promotes apoptosis in triple-negative breast cancer (TNBC) cells[1].Treatment with EC359 at 100 nM for 12 hours in BT549 cells significantly decreases the expression of several known STAT3 target genes, including STAT1, TGFB1, JUNB, MCL-1, etc[1].In MDA-MB-231 and BT-549 cells, EC359 treatment at 100 nM for 1 hour substantially reduces STAT3 activation induced by LIF, OSM, and CNTF. Additionally, EC359 treatment leads to a significant decrease in the phosphorylation of AKT, mTOR, S6, and ERK1/2. Furthermore, EC359 treatment enhances the phosphorylation of proapoptotic p38MAPK in BT549 cells[1]. |
| In vivo | Subcutaneous injection of EC359 at a dose of 5 mg/kg, administered three days per week for 25 days in female athymic nude mice, significantly reduces tumor progression. Importantly, the body weights of mice in the EC359-treated groups remain unchanged, confirming the low toxicity of EC359[1]. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (184.95 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.4 mM), Sonication is recommended. |
| Keywords | leukemia inhibitory factor receptor | EC359 | EC 359 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $117.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY